Advertisement
Clinical MedicineIn-Press PreviewInfectious diseaseVirology Free access | 10.1172/JCI144930
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by
Boonyaratanakornkit, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Morishima, C. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Selke, S. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Zamora, D. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by McGuffin, S. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Shapiro, A. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Campbell, V. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by McClurkan, C. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Jing, L. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Gross, R. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Liang, J. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Postnikova, E. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Mazur, S. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Lukin, V. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Chaudhary, A. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Das, M. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Fink, S. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Bryan, A. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by
Greninger, A.
in:
JCI
|
PubMed
|
Google Scholar
|
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by
Jerome, K.
in:
JCI
|
PubMed
|
Google Scholar
|
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Holbrook, M. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Gernsheimer, T. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Wener, M. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by Wald, A. in: JCI | PubMed | Google Scholar
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
3Department of Medicine, University of Washington, Seattle, United States of America
4Department of Global Health, University of Washington, Seattle, United States of America
5Division of Clinical Research, National Institutes of Health, Frederick, United States of America
6PCE Labs, Kearney, Chicago, United States of America
Find articles by
Koelle, D.
in:
JCI
|
PubMed
|
Google Scholar
|
Published December 15, 2020 - More info
Background: SARS-CoV-2-specific antibodies may protect from reinfection and disease, providing rationale for administration of plasma containing SARS-CoV-2 neutralizing antibodies (nAb) as a treatment for COVID-19. Clinical factors and laboratory assays to streamline plasma donor selection, and the durability of nAb responses, are incompletely understood.
Methods: Potential convalescent plasma donors with virologically-documented SARS-CoV-2 infection were tested for serum IgG to SARS-CoV-2 spike protein S1 domain, nucleoprotein (NP), and for nAb.
Results: Amongst 250 consecutive persons, including 27 (11%) requiring hospitalization, studied a median of 67 days since symptom onset, 97% were seropositive on one or more assays. Sixty percent of donors had nAb titers ≥1:80. Correlates of higher nAb titer included older age (adjusted odds ratio [AOR] 1.03/year of age, 95% CI 1.00-1.06), male sex (AOR 2.08, 95% CI 1.13-3.82), fever during acute illness (AOR 2.73, 95% CI 1.25-5.97), and disease severity represented by hospitalization (AOR 6.59, 95% CI 1.32-32.96). Receiver operating characteristic (ROC) analyses of anti-S1 and anti-NP antibody results yielded cutoffs that corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. NAb titers declined in 37 of 41 paired specimens collected a median of 98 days (range, 77-120) apart (P<0.001). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses.
Conclusions: Nab titers correlated with COVID-19 severity, age, and sex. Standard commercially available SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing. Functional nAb levels were found to decline and a small proportion of persons recovered from COVID-19 lack adaptive immune responses.